Back to Resource Library
Webinar Description:This webinar will review and share the most recent advances of cell & gene therapy and emerging technologies in malignant brain tumor treatment, the development of newer generation of chimeric antigen receptor-T cells for cancer treatment, as well as the clinical experiences of using mesenchymal stem cells to treat spinal cord injury patients. Three neurosurgeons from Taiwan will share their clinical and research experiences during their clinical career in the United States and Taiwan.
Advances of Cell & Gene Therapy: Neurosurgeons’ Contributions from Taiwan An ISCT Asia Regional Executive Committee WebinarPart 4 of 4 of the ISCT Asia Regional Webinar Series
Sponsored in part by:
Oscar Lee, MD, PhD Immediate Past Asia Regional VP, ISCTVice SuperintendentChina Medical University HospitalTaiwan
Professor Oscar Lee, MD, PhD is an internationally renowned orthopaedic surgeon-scientist who works on basic science and translational application of mesenchymal stromal cells. He has published more than 140 peer-reviewed stem cell research-related papers with a total citation of more than 10,000 times. He is now Vice Superintendent of China Medical University Hospital and Distinguished Professor of China Medical University in Taichung, Taiwan. Also, Professor Lee is the immediate past Vice President of ISCT, Asia Region.
John Kuo, MD, PhDVice PresidentChina Medical UniversityTaiwan
Emerging Therapeutic Strategies for Malignant Brain TumorsDr. John S. Kuo, MD, PhD is currently the Vice President for Medical Affairs of China Medical University. With his clinical excellence and professional achievements from top US universities and academic medical centers, Dr. Kuo helps advance Taiwan’s biomedical field to the world class level and cultivate a new generation of talents to further contribute to our society.Dr. Kuo is an internationally renowned neurosurgeon specializing in complex brain tumor surgery, pituitary surgery and stereotactic radiosurgery. He has created and led multidisciplinary clinical programs of excellence. Dr. Kuo led and co-authored influential national guidelines for brain tumor clinical management and is a leader in the Brain Tumor Executive Committee and other major US neurosurgery, neuro-oncology, and medical societies. Along with outstanding clinical performance, Dr. Kuo has received many research grants and academic honors. He was elected to the American Academy of Neurological Surgeons as a top US academic neurosurgeon out of over 5000 US/Canadian neurosurgeons and elected to the Society of University Surgeons as a top US surgeon across all surgical specialties. Over many years, Dr. Kuo was chosen by his peers as one of America’s Top Surgeons and Castle Connolly America’s Top Doctors.
Der-Yang Cho, MD, PhD SuperintendentChina Medical University HospitalTaiwan
Development of Chimeric Antigen Receptor-T cells for Cancer TreatmentProfessor Der-Yang Cho, MD, PhD is the Superintendent of China Medical University Hospital, in Taichung, Taiwan.
Cheng-Di Chiu, MD, PhD Director of Minimal Invasive Spine, Department of NeurosurgeryDeputy Director of Spine SurgeryChina Medical University HospitalTaiwan
Treatment of Spinal Cord Injury Patients with Mesenchymal Stem Cells: Sharing of Clinical ExperiencesDr. Cheng-Di Chiu is a clinical-scientist and a neurosurgeon of China Medical University and University Hospital. His work mainly focuses on the biological mechanism participated in the formation/progression of hemorrhagic stroke by studying the key cell types and immunological factors which regulate the integrity of blood-brain barrier in early period of injury. He also investigates surgical and interventional approaches used to mitigate symptoms from disc degenerative disease. As a member of CMUH Spine Center, he recently designs and performs MSC-based therapy for sub-acute stage spinal cord injury, which was one of the leading protocol accepted by Taiwanese government and has been launched in CMUH since May 2021.
© 2021 ISCT. All rights reserved.
Site by eConverse Media